Yasmine Wasfi

4.3k total citations · 2 hit papers
40 papers, 3.2k citations indexed

About

Yasmine Wasfi is a scholar working on Immunology, Physiology and Dermatology. According to data from OpenAlex, Yasmine Wasfi has authored 40 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 20 papers in Physiology and 15 papers in Dermatology. Recurrent topics in Yasmine Wasfi's work include Psoriasis: Treatment and Pathogenesis (23 papers), Dermatology and Skin Diseases (15 papers) and Asthma and respiratory diseases (10 papers). Yasmine Wasfi is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (23 papers), Dermatology and Skin Diseases (15 papers) and Asthma and respiratory diseases (10 papers). Yasmine Wasfi collaborates with scholars based in United States, Canada and Germany. Yasmine Wasfi's co-authors include B. Randazzo, Yaung‐Kaung Shen, Shu Li, Kenneth B. Gordon, Kristian Reich, Kim Papp, C.E.M. Griffiths, Michael Song, Alexa B. Kimball and Philippe Szapary and has published in prestigious journals such as New England Journal of Medicine, Neurology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Yasmine Wasfi

37 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

2017 637 citations Andrew Blauvelt, Kim Papp et al. Journal of the American Academy of Dermatology profile →
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

2017 537 citations Kristian Reich, April W. Armstrong et al. Journal of the American Academy of Dermatology profile →

Peers

Countries citing papers authored by Yasmine Wasfi

Since Specialization

Citations

This map shows the geographic impact of Yasmine Wasfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasmine Wasfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasmine Wasfi more than expected).

Fields of papers citing papers by Yasmine Wasfi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasmine Wasfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasmine Wasfi. The network helps show where Yasmine Wasfi may publish in the future.

Co-authorship network of co-authors of Yasmine Wasfi

This figure shows the co-authorship network connecting the top 25 collaborators of Yasmine Wasfi. A scholar is included among the top collaborators of Yasmine Wasfi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasmine Wasfi. Yasmine Wasfi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Effects of Molgramostim on Respiratory Health-related Quality of Life and Patient-reported Outcomes in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) 2025 ·American Journal of Respiratory and Critical Care Medicine ·Ali Ataya, Bruce C. Trapnell, Yoshikazu Inoue, Francesco Bonella, (unknown), Cormac McCarthy, Bryce R. H. Robinson, (unknown), Yasmine Wasfi, (unknown)	0
2	S107 Molgramostim improves pulmonary gas exchange in patients with autoimmune pulmonary alveolar proteinosis (aPAP): results from the IMPALA-2 phase 3 clinical trial 2024 ·Cormac McCarthy, (unknown), Yoshikazu Inoue, Francesco Bonella, Tao Wang, B. Robinson, Robert A. Fleming, Yasmine Wasfi, R K Pratt	0
3	Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility 2023 ·Human Molecular Genetics ·Shu‐Yi Liao, Sean Jacobson, Nabeel Hamzeh, Daniel A. Culver, (unknown), (unknown), (unknown), Karin Pacheco, Divya Patel, Yasmine Wasfi, Laura L. Koth, Carl D. Langefeld, Sonia M. Leach, (unknown), Courtney G. Montgomery, Lisa A. Maier, Tasha E. Fingerlin, (unknown)	10
4	Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02) 2023 ·Journal of Neurology ·Barry J. Byrne, Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic, Paula R. Clemens, Özlem Göker-Alpan, Xue Ming, Mark S. Roberts, Matthias Vorgerd, Kumaraswamy Sivakumar, Ans T. van der Ploeg, Mitchell Goldman, (unknown), Fred Holdbrook, (unknown), Elfrida R. Benjamin, Franklin K. Johnson, (unknown), Yasmine Wasfi, Tahseen Mozaffar	14
5	LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2 2018 ·(unknown), April W. Armstrong, Peter Foley, Yasmine Wasfi, Michael Song, Yaung‐Kaung Shen, Shu Li, Ernesto J. Muñoz‐Elías, B. Randazzo, Kristian Reich	3
6	Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study 2018 ·Journal of the European Academy of Dermatology and Venereology ·Kenneth B. Gordon, April W. Armstrong, Chenglong Han, Peter Foley, Michael Song, Yasmine Wasfi, Yin You, Yaung‐Kaung Shen, Kristian Reich	60
7	Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies 2018 ·British Journal of Dermatology ·Kristian Reich, Kim Papp, April W. Armstrong, Yasmine Wasfi, S. Li, Yaung‐Kaung Shen, B. Randazzo, Michael Song, Alexa B. Kimball	53
8	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial breakdown → 2017 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball	637
9	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial breakdown → 2017 ·Journal of the American Academy of Dermatology ·Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Kenneth B. Gordon	537
10	Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial 2017 ·British Journal of Dermatology ·Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin, Michael Song, B. Randazzo, Yasmine Wasfi, Jingzhi Jiang, S. Li, L. Puig	245
11	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis 2015 ·New England Journal of Medicine ·Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C. Prinz, Yasmine Wasfi, Shu Li, (unknown), Philippe Szapary, B. Randazzo, Kristian Reich	242
12	Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire 2014 ·Value in Health ·Steven R. Feldman, Susan D. Mathias, Brad Schenkel, Hilary H. Colwell, Rahul Ganguly, Yasmine Wasfi, B. Randazzo, Chenglong Han	1
13	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up 2013 ·British Journal of Dermatology ·Kim Papp, C.E.M. Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, (unknown), Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich, (unknown)	318
14	The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection 2012 ·British Journal of Dermatology ·Tsen‐Fang Tsai, Vincent Ho, Michael Song, Philippe Szapary, Takeshi Kato, Yasmine Wasfi, S. Li, Yaung‐Kaung Shen, C. Leonardi, (unknown), (unknown)	65
15	Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study 2012 ·Journal of the European Academy of Dermatology and Venereology ·Alexa B. Kimball, Kim Papp, Yasmine Wasfi, Daphne Chan, Robert Bissonnette, Howard Sofen, Newman Yeilding, S. Li, Philippe Szapary, Kenneth B. Gordon, (unknown)	162
16	The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma 2011 ·Respiratory Medicine ·Yasmine Wasfi, César Villarán, Celine Le Bailly De Tilleghem, Steven S. Smugar, William D. Hanley, Theodore F. Reiss, Barbara Knorr	17
17	Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast 2011 ·Allergy and Asthma Proceedings ·Yasmine Wasfi, James P. Kemp, César Villarán, Rachid Massaad, (unknown), Steven S. Smugar, Barbara Knorr, George Philip	10
18	Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African‐Americans 2008 ·Tissue Antigens ·Yasmine Wasfi, Lori Silveira, (unknown), John E. Hokanson, (unknown), Hajime Satō, (unknown), (unknown), K. I. Welsh, R M du Bois, Lee S. Newman, Lisa A. Maier	7
19	A 45-Year-Old Man With Severe Dysphagia and Pulmonary Infiltrates 2007 ·CHEST Journal ·Yasmine Wasfi, Mitchell L. Margolis	8
20	A New Tool To Assess Sarcoidosis Severity 2006 ·CHEST Journal ·Yasmine Wasfi, Cecile S. Rose, James R. Murphy, Lori Silveira, Jan C. Grutters, Yoshikazu Inoue, Marc A. Judson, Lisa A. Maier	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact